Avicanna has completed its first commercial exports of its genetics in the form of feminized cannabis seeds to Peru and Argentina.
The characterization, evaluation and production of these seeds were all completed through Avicanna’s vertical integration at SMGH over the past 3 years and validate the company’s leadership in the breeding and stabilization of cannabis strains in South America.
Peruvian legislation allows for the importation, distribution, and sale of cannabis, its seeds, its extracts and derived products, for medical and scientific research purposes. Current Argentinian legislation allows for the importation, distribution, and sale of cannabis, its seeds, its extracts and derived products, for medical and scientific research purposes related to the treatment of patients with refractory epilepsy under the Exception Access Regime. Argentinian legislation also allows for certain government agencies to cultivate cannabis in collaboration with provincial agencies whom Avicanna is currently supplying with its genetics.
Lucas Nosiglia, President of Avicanna LATAM commented: “After several years of R&D developing our breeding program, we have established a world-renown genetics platform and established a regulatory pathway for the export of our genetics into what is now 4 countries. We are thrilled that our pioneering efforts have enabled us to supply and support our Argentine and Peruvian partners with their long-term medicinal cannabis cultivation programs. With this program we are delivering federally registered genetics that are optimized and standardized for industrial agronomic performance in both greenhouse and outdoor cultivation models.”